Aura Biosciences Q2 net loss $18.3M; cash $162M; Phase 3 trial on track for H2 2023 dosing

Aura Biosciences, Inc.

2023-Q2 EPS reported -$0.95

Net loss $18.3M vs $13.5M in Q2 2022; R&D expenses rose to $15.1M on Phase 3 start-up.
Cash and marketable securities $162.0M; expected to fund operations into H2 2025.
Phase 3 trial of bel-sar for choroidal melanoma enrolling; first patient dosing expected H2 2023; commercial material released.
Key leadership appointments: Bruce Brown (Urologic Oncology), Anthony Daniels (Ocular Oncology), Richard Mountfield (SVP Regulatory).
Phase 1 NMIBC trial ongoing; data expected 2024; Plan Phase 2 in choroidal metastasis in 2024.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aura Biosciences, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was $18.3 million.

Period: the second quarter ended June 30, 2023
Net income: Net loss for the three months ended June 30, 2023 was $18.3 million
Result: reported results

Exact text from the filing

On August 9, 2023, Aura Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Aura Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040136

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.